Clinical trials: Fibrosing Interstitial Lung Disease, active
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Hypersensitivity Pneumonitis
Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
Hypersensitivity pneumonitis (HP) is a diffuse infiltrative pneumonitis (DIP) of immuno-allergic origin, caused by exposure to one or more antigenic substances of organic origin, in genetically predisposed individuals.
- Trial name
- PHSaDom (NCT05988437)
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 162 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT06422884
- Testing
- ENV-101
- Where
- 78 sites in Argentina, Australia and 12 more
- Volunteers
- 213 people
- Sponsor
- Endeavor Biomedicines, Inc.
Sarcopenia
Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact
Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years.
- Trial name
- FRAPID (NCT07004595)
- Testing
- Evaluation of patient frailty
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Progressive Fibrosing Interstitial Lung Disease
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease
This project aims to investigate the potential of non-invasive imaging to identify and monitor the earliest signs and physiological effects of pulmonary fibrosis and resulting cardiac dysfunction in patients with fibrosing…
- Trial name
- NCT05914506
- Testing
- Hyperpolarized xenon-129 MRI
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Interstitial Lung Diseases
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
Interstitial lung diseases (ILDs) are common chronic disease characterized by high mortality and morbidity, also linked to cardiovascular implication.
- Trial name
- AMICI-ILD (NCT06537934)
- Where
- Italy
- Volunteers
- 123 people
- Sponsor
- IRCCS San Raffaele
Lung Diseases, Interstitial
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).
- Trial name
- NCT06440746
- Testing
- Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
- Where
- 33 sites in Russia
- Volunteers
- 138 people
- Sponsor
- R-Pharm International, LLC
Fibrosing Interstitial Lung Disease
Prospective Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted for Acute Respiratory Failure
This prospective, multicenter study focuses on patients with fibrosing interstitial lung diseases (ILD) admitted to intensive care units (ICUs) for acute respiratory failure (ARF).
- Trial name
- PIDREA (NCT06855004)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Assess PID Diagnosis Revision After CMEI Audit, Assess CMEI Recommendations' Impact on Respiratory Health
Domestic Environmental Exposure and Progression of ILD: An Exploratory Case-Control Study
The project titled "Domestic Environmental Exposure and Progression of Progressive or Stable Fibrosing Interstitial Lung Diseases: An Exploratory Case-Control Study" is a Category 3 study involving 60 patients with progressive or…
- Conditions
- Assess PID Diagnosis Revision After CMEI Audit, Assess CMEI Recommendations' Impact on Respiratory Health, ILD Progression and Exposure to Indoor Environnemental Risk, ILD Progression and Exposure to Outdoor Polluants
- Trial name
- EXPODOM-PID (NCT07457502)
- Testing
- Environmental audit of patient housing
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Ville de Paris
Fibrosing Interstitial Lung Diseases, Thoracic Ultrasound
Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease
In this study the investigators want to examine the different ultrasound techniques to assess the patients with lung fibrosis. The investigators want to followup these patients in 1 year to see the changes in lungs, pleura…
- Trial name
- LORD (NCT06844331)
- Testing
- Thoracic ultrasound
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Odense University Hospital
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim